Imerys (NK) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
12 May, 2026Opening remarks and agenda
The meeting was opened with introductions of key executives and board members, confirmation of legal formalities, and appointment of scrutineers for voting.
The agenda, draft resolutions, and voting procedures were outlined, with all required documents made available to shareholders.
Financial performance review
2025 revenue was EUR 3.384 billion, stable year-over-year, with adjusted EBITDA at EUR 546 million, reflecting strong cost control despite adverse forex impacts.
Net income was negative EUR 409 million, mainly due to a EUR 467 million goodwill impairment in the RAC segment, with no cash impact.
Free cash flow before strategic CapEx was EUR 127 million; after CapEx, EUR 78 million, with a sound financial structure and confirmed investment-grade rating.
Q1 2026 showed revenue growth of 0.7% and a 4% increase in adjusted EBITDA at constant exchange rates, driven by volume growth and cost control.
Board and executive committee updates
Pierre Lebreuil was welcomed as the new CFO, bringing 20 years of experience.
Johannes Huth and Michael Ogrinz were introduced as new board members, with their appointments ratified during the meeting.
Annette Messemer and Ian Gallienne stepped down from the board, with acknowledgments for their service.
Latest events from Imerys
- Q1 2026 saw modest growth and margin gains, offset by FX and restructuring impacts.NK
Q1 202629 Apr 2026 - Stable 2025 results, major goodwill impairment, and cost savings plus lithium investment ahead.NK
Q4 202520 Feb 2026 - Strong 2024 results, higher dividend, strategic progress, and all resolutions approved.NK
AGM 20253 Feb 2026 - H1 2024 adjusted EBITDA rose 11% to €384m, margin 20%, with strong cash flow and guidance.NK
H1 20242 Feb 2026 - Nine-month EBITDA margin rose to 19.2% as full-year guidance is confirmed.NK
Q3 202417 Jan 2026 - Organic growth and sustainability progress offset margin pressure from joint venture declines.NK
Q1 202524 Dec 2025 - Organic growth, margin expansion, and strong ESG progress with robust 2025 outlook.NK
H2 202415 Dec 2025 - Stable H1 2025 sales and EBITDA, but net income fell; full-year EBITDA guidance reaffirmed.NK
Q2 202516 Nov 2025 - Revenue down 0.7% YTD; cost controls and strategic growth moves support profitability.NK
Q3 20251 Nov 2025